
ATHE
Alterity Therapeutics Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.000
Open
5.870
VWAP
6.48
Vol
258.16K
Mkt Cap
60.31B
Low
5.850
Amount
1.67M
EV/EBITDA(TTM)
--
Total Shares
8.73M
EV
142.89M
EV/OCF(TTM)
--
P/S(TTM)
303.64
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Show More
1 Analyst Rating

83.21% Upside
Wall Street analysts forecast ATHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

83.21% Upside
Current: 6.550

Low
12.00
Averages
12.00
High
12.00

83.21% Upside
Current: 6.550

Low
12.00
Averages
12.00
High
12.00
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$8 → $12
2025-01-30
Reason
Maxim Group
Jason McCarthy
Price Target
$8 → $12
2025-01-30
Maintains
Strong Buy
Reason
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$8
2024-12-12
Reason
Maxim Group
Jason McCarthy
Price Target
$8
2024-12-12
Initiates
Strong Buy
Reason
Maxim initiated coverage of Alterity Therapeutics with a Buy rating and $8 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Alterity Therapeutics Ltd (ATHE.O) is -9.08, compared to its 5-year average forward P/E of -18.76. For a more detailed relative valuation and DCF analysis to assess Alterity Therapeutics Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-18.76
Current PE
-9.08
Overvalued PE
82.75
Undervalued PE
-120.27
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.47
Current EV/EBITDA
-7.26
Overvalued EV/EBITDA
0.74
Undervalued EV/EBITDA
-1.68
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued
5Y Average PS
9.77
Current PS
38.95
Overvalued PS
16.75
Undervalued PS
2.78
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATHE News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
07:30:15
Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study

2025-05-05 (ET)
2025-05-05
07:36:10
Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434

2025-04-30 (ET)
2025-04-30
07:40:44
Alterity Therapeutics reports cash balance of A$17.96M as of March 31

Sign Up For More Events
Sign Up For More Events
News
3.5
07-24NewsfilterPinnedAlterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
9.5
07-11BenzingaWhy Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
9.0
05-07NewsfilterAlterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Sign Up For More News
People Also Watch

NTWK
NetSol Technologies Inc
4.150
USD
-2.12%

AACG
ATA Creativity Global
1.007
USD
-6.76%

MRNS
Marinus Pharmaceuticals Inc
0
USD
0.00%

AAME
Atlantic American Corp
2.270
USD
0.00%

GRYP
Gryphon Digital Mining Inc
1.210
USD
+0.83%

FLUX
Flux Power Holdings Inc
1.830
USD
-6.63%

STBX
Starbox Group Holdings Ltd
0
USD
-9.95%

XAIR
Beyond Air Inc
3.200
USD
-3.61%

CVM
CEL-SCI Corp
8.200
USD
+19.71%

VCIG
VCI Global Ltd
1.230
USD
+36.20%
FAQ

What is Alterity Therapeutics Ltd (ATHE) stock price today?
The current price of ATHE is 6.55 USD — it has increased 15.32 % in the last trading day.

What is Alterity Therapeutics Ltd (ATHE)'s business?

What is the price predicton of ATHE Stock?

What is Alterity Therapeutics Ltd (ATHE)'s revenue for the last quarter?

What is Alterity Therapeutics Ltd (ATHE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Alterity Therapeutics Ltd (ATHE)'s fundamentals?

How many employees does Alterity Therapeutics Ltd (ATHE). have?
